Clinical trial NCT05537688: Identification of Graphic Markers of Neurocognitive Disorders (MG)
Official title: Identification of Graphic Markers of Neurocognitive Disorders Such as Primary Progressive Aphasia (PPA) and Early-stage Alzheimer's Disease (AD) (MG)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer Disease
Primary Progressive Aphasia
Neurocognitive Disorders
Keywords: Graphic markers
Lead sponsor: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Sponsor class: OTHER_GOV
First posted: 2022-09-13
Enrollment: 53
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be selected from the patient files of the principal investigator.

Brief summary: The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity. However, several studies have shown that graphic parameters are affected in people with moderate to severe Alzheimer's disease. The use of new technologies in the study and analysis of the abilities of people with neurodegenerative diseases is increasingly recommended. The use of a digital tablet with a stylus makes it possible to objectivize the kinematic parameters of writing (pressure, inclination, speed, jerk, time of writing task) and thus would allow a low-cost diffusion of this technology in particular by including it in already existing screening batteries.

The overall objective of the project is to characterize and compare the graphical markers of a writing task, either language-based (writing words, non-words, sentences) or non-language-based (drawing shapes), in patients with PPA, early-stage Alzheimer's disease (i.e., at the stage of minor neurocognitive disorders and major neurocognitive disorders at the beginning of the disease), and in people with no cognitive disorders.


Eligibility criteria: Inclusion Criteria:

* = \> 50 years old

For control group :

* not have a diagnosis of minor or major neurocognitive disorder.

For AD :

* Have mild stage Alzheimer's disease: 1/ Be diagnosed according to ICD-10 criteria for the following conditions: Alzheimer's disease and 2/ Have an MMSE score between 20 and 27, corresponding to a major TNC of mild stage or have a diagnosis of minor TNC with an MMSE score between 25 and 30, the validity period of a previously done MMSE is 3 months.

For PPA :

* Have Primary Progressive Aphasia according to the Gorno-Tempini criteria (Gorno-Tempini et al., 2011) and have an MMSE score between 20 and 27, corresponding to major mild TNC or have a diagnosis of minor TNC with an MMSE score between 25 and 30, the validity period of a previously made MMSE is 3 months.

Exclusion Criteria:

* Presence of pathologies of the dominant upper limb(s) (left, right or ambidextrous lateralization) disabling such as osteoarthritis, finger amputation, etc.
* History of stroke.
* Illiterate person.
* Participate in a concurrent experimental clinical study, to avoid interference with our study.
* Not understand oral and written French. The speakers are French-speaking and the language task is performed in French.

Primary outcomes:
measure: Average writing pressure
timeFrame: 3 months
measure: Average writing speed
timeFrame: 3 months
Secondary outcomes:
measure: Physical and autonomy frailty
timeFrame: 3 months
measure: Socio-demographic characteristics
timeFrame: 3 months
measure: Stage of the neurodegenerative disease
timeFrame: 3 months
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: CRIUGM
state: Quebec
Study officials:
References: